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Cardiomyocyte proliferationInterventions to effect therapeutic cardiomyocyte renewal have received considerable interest of late. Such inter-
ventions, if successful, could give rise to myocardial regeneration in diseased hearts. Regenerative interventions
fall into two broad categories, namely approaches based on promoting renewal of pre-existing cardiomyocytes
and approaches based on cardiomyogenic stem cell activity. The latter category can be further subdivided into ap-
proaches promoting differentiation of endogenous cardiomyogenic stem cells, approacheswherein cardiomyogenic
stem cells are harvested, ampliﬁed or enriched ex vivo, and subsequently engrafted into the heart, and approaches
wherein an exogenous stem cell is induced to differentiate in vitro, and the resulting cardiomyocytes are engrafted
into the heart. There is disagreement in the literature regarding the degree to which cardiomyocyte renewal occurs
in the normal and injured heart, themechanism(s) bywhich this occurs, and the degree towhich therapeutic inter-
ventions can enhance regenerative growth. This review discusses several caveats which are encountered when
attempting to measure cardiomyocyte renewal in vivowhich likely contribute, at least in part, to the disagreement
regarding the levels at which this occurs in normal, injured and treated hearts. This article is part of a Special Issue
entitled: Cardiomyocyte biology: Cardiac pathways of differentiation, metabolism and contraction.
© 2012 Elsevier B.V. All rights reserved.The regenerative potential of the adult myocardium in cold-blooded
animals is well established. Indeed, the initial observation suggesting
regenerative growth following injury, in frogs, was reported in 1875
[1]. A substantive body ofwork, largely by the Rumyantsev (summarized
in [2]) and Oberpriller [3–7] laboratories in the 1970s–1980s, further
characterized this phenomenon, providing evidence that cardiomyocyte
proliferation was a major component of the phenomenon. More recent
work established a similar regenerative phenotype in zebraﬁsh [8], a par-
ticularly important observation given the suitability of that species
for mutational screens. Importantly, the magnitude of cardiomyocyte
renewal in lower invertebrates and reptiles is sufﬁciently high so as to
be readily detected by simple histologic analysis at various time points
post-injury.
More recent studies examining potential therapeutic interventions
to promote cardiac regeneration speak of challenging “the old dogma”
that the adult mammalian heart lacks regenerative potential. In fact,
the notion of ongoing cardiomyocyte renewal in the mammalian
heart is not a new idea. Many studies have examined cardiomyocyte
cell cycle activity in normal and injured adult hearts, and the presence
of ongoing cardiomyocyte renewal has been long accepted. Rather,ocyte biology: Cardiac pathways
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cine, 1044 W. Walnut Street,
: +1 317 278 9298.
rights reserved.the debate in the literature resides in the magnitude at which this oc-
curs. For example, in the uninjured adult rat heart, values for ventricular
cardiomyocyte cell cycle activity (which is often used as a surrogate
marker for cardiomyocyte renewal) varied from 0 to 3.15% (reviewed
in [9]). This variation likely reﬂects a number of factors, including
the duration of the cell cycle marker being scored. For example, the
duration of S-phase is much greater than that of M-phase, and as
such assays monitoring cardiomyocyte DNA synthesis (i.e., tritiated
thymidine or bromodeoxyuridine incorporation) would by default
give rise to a proportionally higher renewal rate than assays moni-
toring the presence of mitotic ﬁgures. Other markers (such as Prolif-
erating Cell Nuclear Antigen or Ki67 immune reactivity) which are
expressed throughout much of the cell cycle would give rise to
even higher renewal rates.
Another factor contributing to the high level of variation reported
for baseline cardiomyocyte cell cycle activity is the accuracy with
which cardiomyocytes (and in particular cardiomyocyte nuclei) are
identiﬁed. It has been argued that the use of confocal microscopy, in
combination with immune ﬂuorescence visualization of a cytoplas-
mic marker (as for example, Troponin T) and a cell membrane marker
(as for example, wheat germ agglutinin or laminin) can be used to
unequivocally identify cardiomyocyte nuclei in tissue sections [10].
In practice, the z-axis resolution of confocal microscopy is insufﬁcient
to resolve non-cardiomyocyte nuclei in close (i.e., b0.5 microns)
proximity to cardiomyocyte cytoplasm [11,12], thus precluding accu-
rate cardiomyocyte nucleus identiﬁcation in some instances. This is
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more than 90% of the mass of the heart, they constitute only 20% of
the total cell number.
This caveat was nicely illustrated in experiments using a transgenic
mousewherein the cardiomyocyte-restricted alphamyosin heavy chain
promoter [13] targeted expression of a nuclear localized beta-
galactosidase reporter (the transgene is depicted in Fig. 1A). These
mice (designated MHC-nLAC mice [14]), can be used to identify
cardiomyocyte nuclei in tissue sections by simple reaction with a
chromogenic beta-galactosidase substrate (i.e., X-GAL; Fig. 1B, blue
signal) or by beta-galactosidase immune ﬂuorescence (Fig. 1C,
green signal). Sections from these hearts were processed for beta-
galactosidase (to identify cardiomyocyte nuclei) and Troponin T (to
identify cardiomyocyte cytoplasm) immune reactivity, and stained
with wheat germ agglutinin (to identify cell membranes) and Hoechst
(to all identify nuclei). The sections were then imaged via confocal mi-
croscopy using a high numerical aperture objective, and Z-axis stacks
comprising 42 steps at intervals of 0.24 μm for each imaged volume
were generated. Observers were supplied with image volumes
containing the Troponin T, wheat germ agglutinin and Hoechst sig-
nals, and were asked to identify the origin (i.e., cardiomyocyte or
non-cardiomyocyte) of each nucleus. These results were then direct-
ly compared to those obtainedwith beta-galactosidase immune ﬂuo-
rescence within the same tissue volume. Signiﬁcant error rates were
observed [15], underscoring the subjectivity of traditional confocal
microscopic analyses for cardiomyocyte nuclear identiﬁcation.
We have used the MHC-nLAC mice to monitor cardiomyocyte cell
cycle activity in normal adult hearts. For these experiments, the mice
received a single injection of tritiated thymidine, and were sacriﬁced
four hours later. The hearts were harvested, sectioned, and processedMHC 
PromoterA
B C
Fig. 1. Detection of cardiomyocyte nuclei in MHC-nLAC transgenic mice. A. Schematic depic
sequence plus Exons 1, 2 and the non-coding region of Exon 3. The protamine terminator wa
of transgene-encoded transcripts. B. Low power image of a section from an adult MHC-nLAC
strate. Cardiomyocyte nuclei appear blue. C. Low power image of a section from an ad
Cardiomyocyte nuclei are identiﬁed by green ﬂuorescence.for X-GAL reaction (to identify cardiomyocyte nuclei) and autoradi-
ography (to identify S-phase nuclei). A typical cardiomyocyte in
S-phase is shown in Fig. 2A; using this approach only 0.0005% of the
cardiomyocyte nuclei in adult hearts were thymidine positive [16].
While this is a relatively low rate of cell cycle activity, it is important
to note that it represents only those cardiomyocytes which were syn-
thesizing DNA during the 4 h labeling session. If one assumes a linear
relationship, multiplying by 6 would provide a daily cell cycle rate
(i.e., 24 h/4 h), and multiplying further by 365 would provide a year-
ly rate. This would predict a cardiomyocyte renewal rate of 1.09% per
year in the uninjured adult mouse heart, assuming that the DNA syn-
thesis events culminated in cytokinesis. This value is remarkably close
to the human cardiomyocyte renewal rate calculated by the Frisén
laboratory [17]. These later experiments utilized a carbon dating ap-
proach that exploited the spike in atmospheric radioactive carbon
resulting from numerous above-ground nuclear tests in the 1950s
and 1960s, in combination with a cardiomyocyte nuclear-speciﬁc
marker, and predicted an annual cardiomyocyte renewal rate of 1%
per year in young adults.
Monitoring cardiomyocyte DNA synthesis per se does not neces-
sarily discriminate between renewal via proliferation of pre-existing
cardiomyocytes vs. cardiomyogenic differentiation of stem cells. For
example, the human experiment was cumulative in nature, and could
detect DNA synthesis events in pre-existing cardiomyocytes as well
as in stem cells which subsequently differentiated into cardiomyocytes.
In contrast, the labeling period in the mouse experiment was too short
to detect de novo cardiomyogenic events; it could only detect DNA
synthesis events in pre-existing cardiomyocytes. The fact that the
normalized mouse data agreed well with the cumulative human data
provides circumstantial data suggesting that the primary mechanismNuclear
Beta-galactosidase
Reporter
Protamine
Terminator
tion of the MHC-nLAC transgene. The MHC promoter consists of 4500 bp of 5′ ﬂanking
s inserted down-stream of the beta-galactosidase sequence to ensure proper processing
transgenic heart following reaction with X-GAL, a chromogenic beta-galactosidase sub-
ult MHC-nLAC transgenic heart processed for beta-galactosidase immune reactivity.
A B
Fig. 2. Use of tritiated thymidine incorporation in conjuction with the MHC-nLAC reporter transgene to detect cardiomyocyte cell cycle activity in normal and injured hearts. A.
Cardiomyocyte DNA synthesis in a normal heart from a mouse receiving a single injection of tritiated thymidine. The image shows a section following X-GAL reaction and autora-
diography. An S-phase cardiomyocyte nucleus is identiﬁed by the presence of silver grains over blue signal. B. Detection of cardiomyocyte (arrow) and non-cardiomyocyte (arrow-
heads) DNA synthesis at the peri-infarct zone in a mouse carrying the MHC-nLAC reporter transgene following a single injection of tritiated thymidine. Insert shows the Hoechst
epiﬂuorescence signal from the same ﬁeld.
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ation of pre-existing cardiomyocytes.
There are also many reports examining cardiomyocyte renewal
following myocardial injury in mammalian hearts. Once again, the
reported levels of cardiomyocyte cell cycle re-entry, and the degree
to which this results in cardiomyocyte renewal, varied greatly
between laboratories and appeared to be greatly inﬂuenced by the
age of the animal at the time of injury, the method used to monitor
cell cycle entry, the anatomical position of the cells studied, and the
timing of the analyses post-injury (reviewed in [9]). With regards to
age at the time of injury, studies in rats from the Gerdes laboratory
clearly demonstrated that high levels of cardiomyocyte renewal could
be induced during early post-natal life [18], a ﬁnding that was recently
conﬁrmed by surgical interventions in mice [19]. In mice, this potential
for renewal was markedly decreased by post-natal day 7, which coin-
cides with the cessation of developmental cardiomyocyte proliferation
in normal mice [20].
With regards to the method used to monitor cardiomyocyte re-
newal, all of the caveats raised above regarding the nuances of a
given cell cycle marker, as well as the identiﬁcation of cardiomyocyte
nuclei, in normal tissue are also applicable when examining injured
tissue. Indeed, since injury results in a massive inﬂux of immune
cells, as well as a pronounced ﬁbrotic response which is accompanied
by the ampliﬁcation of myoﬁbroblasts, nuclear identiﬁcation becomes
even more problematic. Once again this is nicely illustrated using the
MHC-nLAC mice. Fig. 2B shows an image of the peri-infarct zone of an
MHC-nLAC mouse which received a single injection of tritiated thy-
midine 2 weeks following permanent coronary artery ligation. The
heart was harvested four hours later and sectioned, and the section
was reacted with X-GAL and processed for autoradiography. A single
S-phase cardiomyocyte nucleus (arrow) and multiple S-phase non-
cardiomyocyte nuclei (arrowheads) are seen. A vast increase in the
number of non-myocytes is evident in the Hoechst image from the
same ﬁeld (insert). Retrospective analysis from our laboratory revealed
an average border zone (deﬁned arbitrarily as 500 microns from the
myocardium/scar interface) cardiomyocyte nuclear labeling index of
roughly 0.1% using this approach.
Given the relatively low levels of renewal, analyses based on cu-
mulative label incorporation have the advantage of circumventing
errors resulting from sampling size. Bromodeoxyuridine, delivered in
drinking water or via implanted osmotic mini-pumps, provides a suit-
able approach. The MHC-nLACmice are also useful for the assessment
of bromodeoxyuridine incorporation. Fig. 3A shows images from an
MHC-nLAC mouse following a single injection of bromodeoxyuridine;
the heart was harvested four hours later and sectioned. The sectionswere then processed for beta-galactosidase (green signal, left panel)
and bromodeoxyuridine (red signal, middle panel) immune reactivity.
The same ﬁeld was also imaged using a dual-channel ﬁlter (right
panel); the S-phase cardiomyocyte nucleus appears yellow due to
the overlay of green beta-galactosidase and red bromodeoxyuridine
signals (indicated by the arrow in all three panels). When infarcted
MHC-nLAC mice were subjected to cumulative labeling analyses
(7 day bromodeoxyuridine infusion using an osmotic mini-pump), a
proportionate increase in the cardiomyocyte labeling index at the in-
farct border zone was observed. However, a dramatic increase in the
non-cardiomyocyte labeling index was also observed (Fig. 3B; image
was captured with a dual-channel ﬁlter, S-phase cardiomyocyte nuclei
are yellow, S-phase non-myocyte nuclei are red), further underscoring
the need to have a non-subjective assay to identify cardiomyocyte
nuclei, particularly when employing cumulative label assays.
Early studies recognized that the elevated level of myocardial re-
newal observed in injured hearts was largely limited to the region
of injury, and that the remote myocardiumwas not markedly affected
(summarized in [2]). Thus, experiments which examine only the in-
farct and/or a limited proximal region of the border zone will by de-
fault report higher renewal rates as compared to experiments which
include more distal regions in the analyses. This in turn contributes
to variation in the reported renewal rates in injured hearts. The
timing of the analyses is also an important consideration, as experi-
ments in rats clearly demonstrated that cell cycle activity reached
maximal levels at two weeks following cryoinjury and then rapidly
subsided [21]. The degree to which cell cycle activation (as evidenced
by S-phase entry) culminates in cytokinesis is also subject to some
debate. This is perhaps best illustrated by examples from infarcted
human hearts, where markedly different conclusions were drawn
based on the inclusion [22] or exclusion [23] of assays to monitor
nuclear envelop breakdown. There are two interesting exceptions to
the low rates of post-injury cardiomyocyte renewal. The Rumyantsev
and Oberpriller laboratories clearly demonstrated atrial cardiomyocyte
renewal following injury to the ventricular myocardium in rats
[2,24–27]. Furthermore, Rumyanstev clearly documented cell cycle
induction in conduction system cells following myocardial injury
(summarized in [2]). These ﬁndings have not been extensively
pursued, presumably because ampliﬁcation of working ventricular
cardiomyocytes is the more relevant clinical target.
As indicated above, short pulse-chase experiments cannot detect
stem-cell mediated cardiomyogenic events (unless the resulting
cardiomyocytes retain cell cycle activity). In contrast, cumulative
label incorporation assays have the potential to detect stem cell
mediated events. Indeed, the notion that cardiomyogenic stem cells
AB
Fig. 3. Use of bromodeoxyuridine incorporation in conjuction with the MHC-nLAC reporter transgene to detect cardiomyocyte cell cycle activity in normal and injured hearts. A.
Cardiomyocyte DNA synthesis in a normal heart from a mouse receiving a single injection of bromodeoxyuridine. The images show the same ﬁeld of a section following processing
for beta-galactosidase (green ﬂuorescence, left panel) and bromodeoxyuridine (red ﬂuorescence, middle panel) immune reactivity. The image in the right panel was captured using
a dual-channel ﬁlter; the S-phase cardiomyocyte nucleus (indicated by the arrow in all three panels) appears yellow due to the overlay of green and red ﬂuorescence. B. Detection of
cardiomyocyte (yellow signal) and non-cardiomyocyte (red signal) DNA synthesis at the peri-infarct zone in a mouse carrying the MHC-nLAC reporter transgene following 7 days
of bromodeoxyuridine infusion. Cardiomyocyte nuclei which did not enter S-phase during the labeling period appear green.
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past ten years. Ironically, the major studies supporting myocardial re-
newal via extrinsic [28] or cardiac-resident [29] stem cell-mediated
cardiomyogenic activity (and which served as a major impetus in pro-
moting the area of research) have proven to be difﬁcult to reproduce,
at least by some groups [30–33].
Perhaps the strongest data supporting the presence of cardiomyogenic
stem cell activity in the adult heart was generated by the Lee laboratory.
These studies used a genetic fate-mapping system comprised of a trans-
gene encoding a conditional, tamoxifen-dependent Cre recombinase
under the regulation of the cardiomyocyte-restricted myosin heavy
chain promoter in conjunction with a ubiquitously-expressed reporter
transgene [34]. Transient exposure to tamoxifen resulted in the genera-
tion of adult mice which expressed enhanced green ﬂuorescent
protein (EGFP) in terminally differentiated cardiomyocytes, and beta-
galactosidase in all other cells. If stem cells undergo a cardiomyogenic
event in these animals, it would give rise to beta-galactosidase express-
ing cardiomyocytes which could be identiﬁed in histologic sections.
Using this approach, Lee and colleagues were able to demonstrate a
progressive increase in beta-galactosidase expressing cardiomyocytes
following myocardial infarction. Although these data provide strong
evidence for cardiomyogenic stem cell activity, it should be noted
that the conversion rate to activate EGFP reporter expression was only
ca. 70%, with the remaining adult cardiomyocytes retaining beta-
galactosidase activity. Consequently, any differential impact of EGFP
vs. beta-galactosidase expression on cardiomyocyte proliferation or
survival (i.e., apoptosis sensitivity) would impact interpretation of
the data. Unfortunately, this incomplete conversion also renders thesensitivity of the model too low to detect a 1% annual cardiomyocyte
renewal rate, as was reported above for non-injured adult mice.
The utility of genetic tracking systems to identify the origins of
“new” cardiomyocytes in vivo ultimately is dependent upon the ﬁdelity
of the reporter systems.A priori, it seemsobvious that themore complex
the reporter system, the greater the potential for ambiguous results.
For example, earlier studies taking advantage of differential folding
rates (and consequently differential activation of epiﬂuorescence) of
cardiac-restricted EGFP and nuclear red ﬂuorescent protein reporters
suggested that zebraﬁsh regeneration resulted via a stem cell-based
mechanism [35]. In contrast, data from a simpler reporter system
suggested cell cycle-based regeneration [36]; subsequent studies vali-
dated this as the main mechanism for myocardial renewal in zebraﬁsh
[37]. As indicated above, incomplete Cre-mediated conversion in the
bigenic mouse system used by Lee and colleagues complicated data
interpretation. Moreover, the suggestion that the MHC promoter may
be active in undifferentiated progenitor cells in some studies [38,39]
raises further concerns with this approach. Despite these concerns and
caveats, genetic tracking systems as described above offer the best
hope for establishing the molecular basis for myocardial renewal. The
onus is on the investigators to employ the judicious use of controls to
establish the limits of their reporter systems, and to restrict data inter-
pretation within these limits.
Concluding thoughts
The presence of cardiomyocyte renewal in the adult heart has
been recognized for over a century. The main disagreements in the
803M.H. Soonpaa et al. / Biochimica et Biophysica Acta 1833 (2013) 799–803ﬁeld pertain to the level at which this occurs in the mammalian heart,
and the underlying mechanism. It is hoped that this review provides
some explanation for the basis of these disagreements. It is encourag-
ing to note that as assays and reagents improve, a consensus with
regards to the magnitude of renewal in normal and injured hearts is
beginning to emerge. It is also likely that consensus will be reached
regarding the underlying mechanism(s) for renewal. In that regard,
it is sobering to note that the mechanism of post-injury myocardial
renewal in zebraﬁsh (which occurs at a very high level and is easily
detected by histology) remained contested for many years.References
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